VIDEO: OncoSec Medical, Inc. (ONCS)

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, and therapeutics and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead program, ImmunoPulse IL-12, is in Phase II development for various indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.